Clinical trials: Carcinoma, Non-Small-Cell Lung Cancer
Non-small Cell Lung Cancer
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: Cohort I: Patients previously treated…
- Trial name
- NCT00359450
- Testing
- BMS-275183 (oral taxane)
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 186 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer, TKI Resistance
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Lung cancer is the second most common malignancy and mortality rate in the world. In the United States and Europe, approximately 10% to 15% of NSCLC patients have epidermal growth factor receptor (EGFR)-sensitive mutations, with…
- Conditions
- Lung Cancer, TKI Resistance, EGFR Sensitive Mutation, Anlotinib
- Trial name
- NCT06048315
- Testing
- Anlotinib, Penpulimab
- Volunteers
- 52 people
- Sponsor
- Degan Lu
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
- Trial name
- NCT06198868
- Testing
- Operable
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Cancer Institute & Hospital
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well CCI-779 works in treating patients with stage IIIB non small cell lung cancer (with pleural effusion) or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00079235
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have recurrent or…
- Trial name
- NCT00005989
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
This single-arm, open-label, phase II clinical study aims to evaluate the progression-Free Survival (PFS) of the combination of Alectinib plus Bevacizumab in untreated and first and second-line chemotherapy failed subjects with…
- Trial name
- NCT03779191
- Testing
- Alectinib, Bevacizumab
- Where
- Mexico
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Robotics, Lung Cancer
SP Robotic Versus VATS Anatomical Pulmonary Resection for Patients With NSCLC
Single-POrt Robotic-assisted thoracic surgery versus single-port video-assisted Thoracic Surgery major pulmonary resection for patients with non-small cell lung cancer (SPORTS trial): a single-center, a single blinded, randomized…
- Trial name
- SPORTS (NCT06202690)
- Testing
- Single-port robotic-assisted thoracic surgery, Single-port video-assisted thoracoscopic surgery
- Volunteers
- 290 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Lung Neoplasm
Brazilian Lung Immunotherapy Study
Immunotherapy with anti-PD-1/PD-L1 agents either as single agents or combined with chemotherapy is now considered the standard of care for patients with non-small-cell lung cancer.
- Trial name
- BLISS (NCT05081674)
- Testing
- Alectinib, Pembrolizumab, Nivolumab
- Where
- Brazil
- Volunteers
- 154 people
- Sponsor
- Hospital Israelita Albert Einstein
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment
Study Rationale: There is increasing evidence that erlotinib improves overall survival in selected patients with stage IIIB-IV NSCLC.
- Trial name
- NCT00840125
- Testing
- erlotinib, docetaxel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Meir Medical Center
Lung Cancer Non Small Cell
Comprehensive Demographics and Clinical Profile of NSCLC Patients
Advances in the treatment of non-small cell lung cancer in the last decade have been significant. Currently, there are several first-line therapeutic options.
- Trial name
- CA209-1529 (NCT06725537)
- Volunteers
- 500 people
- Sponsor
- D'Or Institute for Research and Education
Colorectal Cancer
Lapatinib Plus Trametinib in KRAS Mutant NSCLC
This is an open-label phase I/II multi-center study consisting of two parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of lapatinib combined with trametinib in patients with metastatic KRASm…
- Trial name
- M14LTK (NCT02230553)
- Testing
- Lapatinib, trametinib
- Where
- Netherlands
- Volunteers
- 35 people
- Sponsor
- The Netherlands Cancer Institute
Non-small Cell Lung Cancer (NSCLC)
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without…
- Trial name
- TROPION-Lung17 (NCT07291037)
- Testing
- Datopotamab deruxtecan (Dato-DXd), Docetaxel
- Where
- 206 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
Combination of RAD001 With Carboplatin, Paclitaxel and Bevacizumab in Non-small-cell Lung Cancer (NSCLC) Patients
This 2 step study aims to establish a tolerable dose level and regimen of RAD001 in patients with advanced NCLC not previously treated with systemic therapy.
- Trial name
- NCT00457119
- Testing
- RAD001
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
The Patient-Reported Outcomes in ALK Positive Advanced NSCLC in China
This is a multicenter, prospective, longitudinal observational study designed to evaluate the patient-reported outcomes and safety profiles of patients with ALK positive advanced Non-Small Cell Lung Cancer (NSCLC) who received…
- Trial name
- NCT06586801
- Testing
- Patient-reported outcome
- Volunteers
- 800 people
- Sponsor
- Shanghai East Hospital
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- LEAP-007 (NCT04676412)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Squamous Non-Small Cell Lung Cancer
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
This study will assess the prevalence of epidermal growth factor receptor (EGFR) mutations in newly diagnosed patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT01250119
- Testing
- erlotinib [Tarceva]
- Where
- 22 sites in United Kingdom
- Volunteers
- 688 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Circulating Tumor DNA
NSCLC Liquid Biopsies and Exhaled VOC
The objective of the study is to determine the feasibility of recruiting participants and using sputum, Bronchoalveolar lavage (BAL) and exhaled Volatile Organic Compounds (VOC) in addition to blood, as biological samples for…
- Trial name
- NCT06707519
- Where
- Canada
- Volunteers
- 210 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Non-small Cell Lung Cancer (NSCLC)
A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)
The main aim of this study is to learn about the time from start of mobocertinib to end of treatment with mobocertinib for any reason in Chinese adults with lung cancer who carry a certain gene mutation (epidermial growth factor…
- Trial name
- MEANING-20 (NCT05863819)
- Testing
- No Intervention
- Where
- China
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.